A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats.

@article{Nakamura1999APK,
  title={A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats.},
  author={Jiro Nakamura and Koichi Kato and Yoji Hamada and Mieko Nakayama and Sadao Chaya and Eitaro Nakashima and Keiko Naruse and Yasuhide Kasuya and Ryuichi Mizubayashi and Kazuma Miwa and Yutaka Yasuda and Hideki Kamiya and Kazuharu Ienaga and Fumihiko Sakakibara and Naoki Koh and Nigishi Hotta},
  journal={Diabetes},
  year={1999},
  volume={48 10},
  pages={2090-5}
}
Increased protein kinase C (PKC) activity has been implicated in the pathogenesis of diabetic retinopathy and nephropathy. However, the role of PKC in diabetic neuropathy remains unclear. The present study was conducted to compare the effect of PKC inhibition by a PKC-beta-selective inhibitor, LY333531 (LY), on diabetic nerve dysfunction with that of an aldose reductase inhibitor, NZ-314 (NZ). Streptozotocin-induced diabetic rats were treated with or without LY and/or NZ for 4 weeks, and motor… CONTINUE READING